Mission of AABC

The mission of the Alzheimer’s Association Business Consortium (AABC) is to advance Alzheimer’s disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer’s research and the goals of its member organizations. They provide leadership and direction to the group’s areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new members who are aligned in their commitment to research and innovation. To express interest in joining, please email Dr. Leen Kawas (kawas@m3bio.com), co-chair; Dr. Judy Walker (jwalker@cerecin.com), co-chair; or Dr. Rebecca Edelmayer (rmedelmayer@alz.org), facilitator.

Welcome New Members

AABC is growing! Welcome to:

- **Alexander Lavin – Latent Sciences**
  Latent Sciences is building a real-world data platform powered by novel AI and blood biomarker tech to shift the paradigm of neurodegenerative research and care to be proactive and personalized. [Read more.]

- **Dorothy Ko and Winston Ko – Genervon**
  Genervon is a clinical-stage biopharmaceutical company that discovered the GM6 peptide, a modulator of key biomarkers and defective pathways associated with neurodegenerative disorders. [Read more.]

- **Hugo Geerts – In Silico Biosciences, Inc.**
  In Silico Biosciences, Inc. utilizes CNS quantitative systems pharmacology to provide model based decision support from target validation to personalized medicine in Alzheimer’s disease, Parkinson’s disease, schizophrenia and antipsychotic-induced side effects. [Read more.]

News from AABC Members

**Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer’s Patients**

Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer’s and Parkinson’s disease that are focused on regeneration, today announced the completion of the Phase 1 clinical trial of its lead candidate, NDX-1017, a novel small molecule therapeutic.

The randomized, double-blind, placebo-controlled Phase 1 trial was evaluating NDX-1017 in healthy young and elderly individuals and individuals with Alzheimer’s disease. A total of 88 subjects were enrolled in the study.

Results from the Phase 1 trial will be featured in an oral presentation by Hans J. Moebius, MD, PhD, ECPM, FAAN, Chief Medical Officer of Athira, at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference taking place December 4-7, 2019 in San Diego, CA. [Read more.]

**BrainSpec Now Supports Clinical Research**

BrainSpec can now support clinical research using their automated platform. BrainSpec non-invasively measures brain chemistry using MR spectroscopy. BrainSpec provides quantitative biomarkers for
neurological diseases for patient stratification and treatment monitoring. If interested in learning more, please reach out to alex.zimmerman@brainspecmed.com.

**DiamiR Announces Additional $345,000 Funding from the NIH for Development of CogniMIR™**

DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR $345,000 in supplemental funding under the ongoing Small Business Innovation Research (SBIR) Phase IIB grant of $2,800,000 awarded in 2017. The award will further support development of the company’s targeted diagnostic technology for detection and prediction of progression of Alzheimer’s disease (AD). Read more.

**Imaginostics Applies for SBIR Fast-Track Phase I/II Grant**

Imaginostics, Inc. is a Boston-based diagnostic imaging biotechnology company that is developing innovative quantitative vascular imaging biomarkers for the early detection of Alzheimer’s Disease and Related Dementia (ADRD).

Imaginostics submitted a SBIR Fast-Track Phase I/II grant application to fund the next phase of R&D for their QUTE-CE MRI Vascular Imaging software. Phase I will be a six-month project starting in April 2020 with collaboration with the American College of Radiology to optimize software and methodology and Phase II will be a two-year clinical trial starting in October 2020. Phase II will recruit patients from Massachusetts General Hospital and Alzheimer’s Association TrialMatch®.

**Latent Sciences Founder Presenting at the Powering Precision Health Summit**

Latent Sciences is developing a platform of patent-pending AI and novel blood biomarker tech for early, actionable insights into Alzheimer’s disease. Founder Alexander Lavin will be presenting at the upcoming Powering Precision Health Summit in Barcelona in November. Read more.

**Oasis Diagnostics and Collaborators Receives Funding from Japan to Produce Salivary Malaria Test for Third World Countries**

ERADA Technology Alliance Ltd (ERADA), pioneers of innovative, rapid diagnostic solutions for early detection of infectious diseases, have announced the imminent launch of a world first diagnostic saliva test for malaria.

The saliva-based diagnostic tool, to be marketed by ERADA as a Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART) for subclinical infection, is set to transform malaria detection worldwide in the fight against one of the globe’s most deadly diseases. ERADA will bring the assay to market in collaboration with several partners including Oasis Diagnostics. Read more.

**T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer’s Disease.**

T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced that it has closed on a $15 million financing from a cornerstone investor. These funds, along with support from the National Institute on Aging (NIA), part of NIH, completes the funding needed to begin the PIONEER Study of T3D-959, a novel, metabolic-focused AD drug treatment. Read more.

**Tetra Therapeutics Clinical Trial Enrollment Going Faster Than Expected**

Tetra Therapeutics says it is enrolling patients faster than expected for a clinical trial on a potential new drug to treat Alzheimer’s disease. It now has more than half of the patients needed for the Phase 2 clinical trial on a compound known as BPN14770.
Alzheimer’s Association Digital Biomarkers Workshop  
November 20-21, 2019 | Washington, D.C.

Explore the emerging and rapidly growing field of digital biomarkers across the entire continuum of Alzheimer’s and other dementias. The workshop will focus on digital technologies being developed to assess cognition and function and the translation of these technologies in and outside the clinical setting. Explore what is possible from a technology development perspective (i.e. engineering and design) and what will be impactful for the end user. Participants will discuss the overall technology use implications, needs for validation, developing/aligning existing acceptability measures, and trajectory of integration across multiple domains. The ultimate goal of the workshop is to identify emerging trends and possible future activities to further stimulate the development and implementation of digital cognitive and functional biomarkers for cognitive decline and all dementias. Register now.

Updates in Neuroimaging Webinar  
December 9, 2019 | 5 p.m. ET

You’re invited to attend ISTAART’s Neuroimaging Professional Interest Area (PIA) webinar “Updates in Neuroimaging.” Learn more about various topics and modalities within the neuroimaging space from Liana Apostolova, M.D., MSc, FAAN, Indiana University; Beau Ances, M.D., Ph.D., MSc, Washington University in St. Louis; and Michael Ewers, Ph.D, Ludwig Maximilians-Universitat Munchen.

Click this link to join the webinar.
Password: 783666

Or iPhone one-tap:
US: +16465588656,,614785299# or +17207072699,,614785299#

Or Telephone:
Dia l(for higher quality, dial a number based on your current location):
US: +1 646 558 8656 or +1 720 707 2699
Webinar ID: 614 785 299
International numbers available

Tau2020 Global Conference  
February 12-13, 2020 | Washington, D.C.

Hosted in partnership by the Alzheimer’s Association, Cure PSP and the Rainwater Charitable Foundation

Join leading tau experts from around the world for the Tau2020 Global Conference, February 12-13 in Washington, D.C. Collaborate with your peers from academia, industry, government and the philanthropic sector to discuss key issues impacting the tau research community. Register today and save — early bird registration ends December 2.

Submit an abstract for Tau2020 for the opportunity to share your breaking research with peers and experts in the tau research community. Abstracts are due by December 9.

For more information about sponsorship opportunities, please contact Jay Thompson at jthompson@alz.org.

Neuro4D Conference  
May 11-12, 2020 | Mainz, Germany

The Neuro4D is an international conference on Neuro Degenerative Disease Drug Discovery bringing together drug discovery companies, service and technology providers and academic innovators in the field of proteopathic neurodegenerative diseases in a highly interactive format. Online registration starts in November. Read more.
AABC will hold elections for a new co-chair to replace Leen Kawas. This position will serve with current co-chair Judy Walker beginning in January for one year. A call for nominations and voting will be held in November. Self-nominations are also accepted.

The responsibilities for co-chair include:
1. Monthly calls with the Alzheimer’s Association staff Rebecca Edelmayer and April Ross to plan future events, propose new webinar topics, suggest speakers and discuss new directions.
2. Participate in webinars and in person events
3. Review and edit the quarterly newsletters.
4. Provide leadership and guidance on AABC topics and issues, as time allows.

For voting, each company is allowed only **ONE** vote, if there are several members from the same company, please identify one representative to provide the consensus vote on the company’s behalf. Individuals must be a member of AABC to vote.